Connect with us

News

Biden-Harris administration awards US$558m to improve maternal health

The Biden-Harris administration has pledged to reduce the nation’s high maternal mortality rate

Published

on

The US Department of Health and Human Services (HHS) has announced more than US$558m in funding to improve maternal health.

The Health Resources and Services Administration (HRSA), an agency of HHS, is awarding more than US$440m in funding to expand voluntary maternal, infant, and early childhood home visiting services for eligible families across the US.

In addition, the Centers for Disease Control and Prevention (CDC) announced a new investment of US$118.5m, over five years, to 46 states, six territories and freely associated states to continue building the public health infrastructure to help identify and prevent pregnancy-related deaths.

In 2022, President Biden signed bipartisan legislation that doubles funding for the Maternal, Infant, and Early Childhood Home Visiting programme over five years.

Through this programme, local organisations can provide home visits from nurses, social workers, and other trained health workers who work with families on early and ongoing engagement in prenatal care and postpartum support.

The awards announced this week reflect the first opportunity for states and jurisdictions to receive federal matching funds in addition to their base grants.

“As someone who has spent my entire career fighting for the health and wellbeing of women and children, I am committed to addressing a maternal health crisis in which women across America are dying before, during, and after childbirth at higher rates than in any other developed nation,” said Vice President Kamala Harris.

“That is why I called on states to extend Medicaid postpartum coverage from two months to 12 months and announced the launch of the White House Blueprint for Addressing the Maternal Health Crisis, an unprecedented whole-of-government strategy to improving maternal care.

“Today, we are building on this lifesaving work by awarding more than US$558m to improve maternal health across America. This includes a critical US$440m to support pregnant women, new mothers, and their children through home visiting programmes that will improve health outcomes, child development, and access to resources for years to come.”

Xavier Becerra, HHS secretary, shared: “Bringing home a baby can be stressful. Many new parents face additional challenges such as housing, or income insecurity, which can make the whole situation even more daunting. But we know from decades of research that home visits work – from helping with school readiness and achievement for children to improving health for women.

“President Biden and Vice President Harris know how important it is to support children in their most crucial years of development so they can grow up to be healthy, happy adults. We will continue to make resources and support available, and elevate maternal health issues so that more women and families know that help is available.”

Carole Johnson, HRSA administrator, added: “At the Health Resources and Services Administration, we are deeply committed to removing barriers to care for expectant and new mums and babies who face too many hurdles getting the support that they need.

“That’s why – thanks to the leadership of the President and Vice President – we were able to work closely with bipartisan leaders in Congress to grow the home visiting programme to give more mums and babies a trusted home visiting partner to help their families in ways large and small to be healthy, feel supported, access healthcare services, nurture their child’s development, and give families every opportunity to thrive.”

Wanda Barfield, director of CDC’s division of reproductive health, said every pregnancy-related death is a tragedy for the family and the community.

“Thanks to MMRCs, we know more about the causes and circumstances around pregnancy-related deaths, and we have actionable recommendations to prevent future deaths,” she explained.

“This investment will support more jurisdictions in their critical work to save mothers’ lives.”

To receive the Femtech World newsletter, sign up here.

Menopause

Medichecks acquires My Menopause Centre to expand specialist hormone health services

Published

on

Digital diagnostics company Medichecks has acquired specialist menopause health platform and clinic My Menopause Centre.

The deal is part of Medichecks’ move into clinical services and follows its earlier purchase of Leger Clinic, creating what the company describes as a hormone health offering for women and men across the UK.

Medichecks and My Menopause Centre will combine digital services with clinical governance. The acquisition aims to enhance Medichecks’ ability to deliver integrated testing, diagnosis and ongoing clinical support.

The combined group plans to grow its specialist hormone health services, supporting patients across the UK with clinical care throughout different stages of their hormone health journey.

Helen Marsden, co-founder of Medichecks, said: “At Medichecks, our mission is to make healthcare more accessible, evidence-based and patient-centred.

“Helen and Clare have built an outstanding, clinically credible platform that is transforming menopause care for women across the UK.

“Medichecks now owns two CQC Outstanding-rated clinics, the only clinics in their respective sectors to achieve this rating, and we are deeply committed to delivering safe, compassionate and patient-centric care.

“We’re proud to continue the founders’ legacy while supporting the next stage of growth, ensuring more women can access high-quality menopause care when they need it most.”

The CQC, or Care Quality Commission, is the independent regulator of health and social care in England.

The acquisition supports Medichecks’ plans to make hormone healthcare more accessible by delivering integrated testing, diagnosis and ongoing clinical support for patients across the UK.

Helen Normoyle, co-founder and chief executive of My Menopause Centre, said: “We set out to build something resilient, clinically credible and scalable, not just fast.

“Our mission has always been to make menopause care compassionate, accessible and grounded in evidence. Medichecks shares that vision.

“Their digital platform, commitment to clinical excellence and patient-centred care make them the ideal partner to take My Menopause Centre into its next chapter.

“This milestone reflects not only a strong product, but a remarkable team and community.

“I’m deeply proud of what we’ve built and excited to see My Menopause Centre grow further under Medichecks’ leadership.”

Continue Reading

Menopause

Menopause specialist Haver joins Midi Health

Published

on

Menopause specialist Dr Mary Claire Haver has been appointed as the first chief agewell officer at virtual care clinic Midi Health.

In the role, Dr Haver will work with Midi’s clinical team to develop the AgeWell platform, described as a proactive health model that integrates perimenopause and menopausal care with metabolic health, bone density, brain health and cardiovascular risk assessment.

The platform aims to provide preventative care targeting what the company describes as the primary drivers of female mortality and disability: heart disease, bone loss and cognitive decline.

Joanna Strober, chief executive and co-founder of Midi Health, said: “Longevity care has historically ignored women’s biology, especially during the critical windows of midlife and menopause.

“At Midi Health, we are committed to extending healthspan, not just lifespan, and making that care accessible to millions of women as a core pillar of their health.

“By collaborating with Dr Haver, we are ensuring women continue to have access to care designed for their bodies, their hormones, and their real lives.”

Dr Haver is board-certified in obstetrics and gynaecology, a Menopause Society certified practitioner, a certified culinary medicine specialist and an adjunct associate professor of obstetrics and gynaecology at The University of Texas Medical Branch.

After a career in academic medicine, Dr Haver founded The Pause Life, described as a science and education-based resource for women navigating perimenopause and the menopause transition.

Through her books, unPaused podcast and digital platform, she has provided education on midlife health.

Dr Mary Claire Haver said: “I have spent my career advocating for women to receive the science-backed, no-nonsense guidance they deserve.

“I chose to partner with Midi Health because they are the only platform with the scale and medical rigour to deliver the kind of care women deserve, regardless of their zip codes.

“Together, we are setting a new standard for proactive, preventative care that meaningfully extends both lifespan and healthspan for women.”

Continue Reading

Events

Kate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live

Published

on

Women’s Health Week USA 2026 has unveiled its first populated agenda, anchored by an opening keynote from Kate Ryder, Founder and CEO of Maven Clinic, and featuring a cross-sector lineup shaping the next phase of scale in women’s health.

You can view the full agenda here.

Taking place May 13–14, 2026, at the New York Academy of Medicine, Women’s Health Week USA brings together the full women’s health ecosystem to focus on one central question: what does it take to move women’s health from innovation to institutional scale?

Kate Ryder will open Day 1 with a keynote drawing on her experience building Maven Clinic into the world’s largest virtual clinic for women’s and family health.

Under her leadership, Maven has partnered with employers and health plans to deliver care across fertility, maternity, postpartum, paediatrics, and menopause at scale.

Her perspective sets the tone for a program centered on commercialisation, partnership, and sustainable growth.

Beyond the opening keynote, the newly released agenda reflects the sector’s growing maturity.

Across two days, the program features 70+ speakers, with representation from leading organizations including the FDA, Planned Parenthood, CVS Health Ventures, Samsung Next, NIH, WHO, and Maven Clinic.

Sessions span investment and deal flow, clinical innovation, regulation, data and technology, and market expansion, alongside dedicated pitch sessions and curated 1:1 matchmaking designed to turn insight into action.

The agenda has been built to facilitate meaningful connections across the ecosystem, with partnerships positioned as the primary driver of scale.

As women’s health continues to attract institutional capital and global attention, Women’s Health Week USA 2026 offers a clear snapshot of where the market is heading, and who is shaping it.

The full agenda is now live, with additional speakers and partners to be announced in the coming months.

View the full programme here.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.